Thermo Fisher Scientific (NYSE:TMO) Posts Earnings Results, Beats Estimates By $0.28 EPS

Thermo Fisher Scientific (NYSE:TMO) announced its quarterly earnings results on Wednesday. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28, FiscalAI reports. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised its 2026 outlook, increasing revenue guidance to $47.7 billion–$48.2 billion, organic growth guidance to 4%, adjusted EPS guidance to $25.13–$25.43, and free cash flow guidance to $7.0 billion–$7.5 billion.
• Third-quarter performance exceeded expectations, with revenue up 9% to $12.14 billion, organic growth of 6%, adjusted EPS up 15% to $6.68, and adjusted operating margin expanding 120 basis points to 24.5%. Growth was led by Pharma Services, clinical research, electron microscopy, and improving biotech demand.
• Management reported continued strengthening in pharma and biotech customer activity, including low-to-mid/high-single-digit growth across key areas, improving biotech funding and confidence, and strong demand for clinical research, bioproduction, and semiconductor-related electron microscopy.
• The quarter benefited from approximately $60 million of net tariff-refund recovery, contributing $0.15 to adjusted EPS, although the company reinvested part of the proceeds in AI deployment, Pharma Services capacity, and employee investments. The refund benefit is largely one-time, while fourth-quarter organic growth guidance remains at 4% after some Pharma Services activity shifted into the third quarter.
• Thermo Fisher highlighted expanding AI capabilities across instruments and services, including AI-enabled cryo-electron microscopy workflows and a clinical research assistant, while the Clario acquisition and bioproduction investments are reportedly generating strong customer adoption and potential revenue synergies.

Thermo Fisher Scientific Stock Up 1.2%

TMO opened at $687.72 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $254.28 billion, a P/E ratio of 28.51, a PEG ratio of 2.83 and a beta of 0.87. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $704.00. The business’s fifty day simple moving average is $640.60 and its 200 day simple moving average is $551.25.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Barclays increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, October 15th. They set a “buy” rating for the company. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $654.05.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 in the last ninety days. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.